Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study - PubMed
7 hours ago
- #treatment discontinuation
- #relapse risk
- #myasthenia gravis
- Optimal timing for treatment discontinuation in myasthenia gravis (MG) patients achieving minimal symptom expression (MSE) remains undefined.
- A prospective cohort study of 196 MG patients who discontinued treatment after achieving MSE found a 55.1% relapse rate over a mean follow-up of 111.10 months.
- Four independent prognostic factors for relapse were identified: onset age ≥ 50 years (risk factor), and rituximab administration, treatment duration ≥ 14.3 months, and time from MSE to discontinuation ≥ 6.1 months (protective factors).
- Common relapse triggers included infection, fatigue, and psychological stress.
- Individualized discontinuation decisions considering younger onset age, prior rituximab use, and adequate treatment and consolidation duration may optimize outcomes.